According to a meta-analysis, thrombin and FXa inhibitor usage is supported in low-risk thrombophilias (i.e. prothrombin gene mutation or high FVIII) without concerns (except for apixaban, due to lack of data) [28]. This evidence concerns the gene F2 and thrombophilia.